---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009689"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:49:40.604543+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M

## Summary
- Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
- Income from operations of $3.4M in FY2025 vs loss of $7.7M in FY2024; net income of $0.3M vs net loss of $9.0M.
- Reduced total operating expenses by 38% to $16.8M, including gains from vendor settlement and royalty liability change.
- Q4 2025 net sales of $9.6M (+35% YoY); operating income of $3.3M vs loss of $1.0M; net income of $2.8M vs loss of $3.0M.
- Since Oct 2025: targeting 55-60% manufacturing cost reduction for PHEXX and SOLOSEC; UAE pricing certificates received.

## SEC filing metadata
- accession: 0001493152-26-009689
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/0001493152-26-009689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009689
- JSON: https://secwatch.observer/filing/0001493152-26-009689.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.